Tobramycin Sulfate 79645-27-5 — China API Manufacturer | USP/EP/BP R&D to Production

China Manufacturing Landscape for Tobramycin Sulfate

Tobramycin Sulfate (CAS 79645-27-5) is an aminoglycoside antibiotic derived from Streptomyces tenebrarius, used primarily for the treatment of serious gram-negative bacterial infections, including Pseudomonas aeruginosa infections in cystic fibrosis patients (inhaled formulation) and ophthalmic infections. China’s position as the world’s dominant aminoglycoside antibiotic producer, built on decades of fermentation technology investment, makes Chinese manufacturers the primary global source for Tobramycin Sulfate API. Our production facility operates dedicated Tobramycin fermentation and purification production lines, exporting to pharmaceutical manufacturers across all major regulated and semi-regulated markets.

The Chinese aminoglycoside manufacturing ecosystem encompasses the entire value chain from strain development and fermentation media production through purification, salt formation, and sterile-grade processing. This complete domestic capability ensures reliable supply chain resilience and cost structures that international competitors cannot replicate, positioning Chinese Tobramycin manufacturers as the preferred API source for both injectable and inhaled dosage form producers worldwide.

Manufacturing Process & Facility

Tobramycin production begins with large-scale aerobic fermentation of Streptomyces tenebrarius in stirred-tank bioreactors ranging from 20,000 to 100,000 liters capacity. The fermentation process, typically running 5-8 days, is managed through automated control of temperature, dissolved oxygen, pH, and nutrient feeding profiles optimized to maximize Tobramycin factor yield while minimizing production of related aminoglycoside co-metabolites including kanamycin and nebramycin factors.

Post-fermentation processing involves filtration to remove mycelia, adsorption chromatography on cation-exchange resins, gradient elution, activated carbon treatment for decolorization, and ultrafiltration/nanofiltration for endotoxin reduction. Sulfate salt formation is achieved by pH-controlled addition of sulfuric acid followed by crystallization or spray drying to yield the final product. For customers requiring sterile-grade Tobramycin Sulfate (for injectable or inhalation formulations), additional processing includes sterile filtration and aseptic crystallization in ISO Class 5 cleanroom environments. Annual capacity exceeds 100 metric tons.

Quality Standards & Multi-Pharmacopeial Compliance

Our Tobramycin Sulfate API meets USP, EP, and BP pharmacopeial requirements simultaneously. Potency by microbiological assay or HPLC-ELSD consistently meets ≥590 μg/mg (on an anhydrous, sulfate-free basis). Related substance levels including kanamycin, nebramycin factors, and other aminoglycoside impurities are controlled within pharmacopeial limits through optimized fermentation and purification processes. Sterile-grade product additionally meets endotoxin specifications of ≤0.25 EU/mg by LAL testing.

Quality testing encompasses microbiological potency assay, HPLC-ELSD composition profiling, sulfate content determination, water content by Karl Fischer, pH measurement, residual solvents, elemental impurities by ICP-MS, particulate matter analysis (for sterile grade), and sterility testing (for sterile grade). Stability programs under ICH Q1A conditions confirm a 36-month shelf life for non-sterile grade and 24-month shelf life for sterile grade under recommended storage conditions.

Regulatory Documentation

We maintain active Drug Master Files with the US FDA (Type II DMF) for both non-sterile and sterile grades of Tobramycin Sulfate, along with EU ASMF documentation and CEP (Certificate of Suitability) from EDQM. WHO Prequalification documentation is available for customers supplying to international procurement programs. Standard regulatory packages include full CTD Module 3.2.S documentation, analytical method validation reports, process validation summaries, quality certificates, and detailed impurity qualification data. For sterile-grade product, additional documentation includes media fill validation reports, environmental monitoring data, and sterile process validation documentation.

Packaging & Logistics

Non-sterile Tobramycin Sulfate is packaged in double PE bag-lined fiber drums of 10 kg or 25 kg. Sterile-grade product is packaged in triple-bagged configurations (PE/aluminum/PE) within sealed stainless steel or fiber drums, with each container validated for sterility maintenance throughout its stated shelf life. All packaging materials are compatibility-tested and qualification data is available. Shipments are arranged via sea freight for bulk non-sterile orders and temperature-controlled air freight for sterile-grade product, with transit times of 5-12 business days by air to major global destinations.

Competitive Pricing & Supply Reliability

Competitive pricing for Tobramycin Sulfate reflects the economies of scale achieved through our high-volume fermentation operations. We offer differentiated pricing for non-sterile and sterile grades, with volume-based discounts available for annual contract commitments. Standard lead times are 3-4 weeks for non-sterile grade and 6-8 weeks for sterile grade. Our large production capacity and maintained finished goods inventory ensure supply continuity even during peak demand periods. Long-term supply agreements with guaranteed pricing and allocation commitments are available for strategic customers requiring assured supply of this critical antibiotic API.

Tobramycin Sulfate Specifications